These novel NO-donor aspirins demonstrate both antiplatelet and vasodilatory properties in preclinical models, suggesting potential as an alternative to standard aspirin.
Answers are grounded in this paper and cite their sources.
Does not support changing aspirin use; leaves open whether NO-donor hybrids offer clinical advantages pending human trials.
A series of (nitrooxyacyloxy)methyl esters of aspirin were synthesized and evaluated as new NO-donor aspirins. Different amounts of aspirin were released in serum from these products according to the nature of nitrooxyacyloxy moiety present. In the aromatic series, there is a rather good linear correlation between the amount of aspirin released and the potencies of the products in inhibiting platelet aggregation induced by collagen. Both the native compounds and the related nitrooxy-substituted acid metabolites were able to relax rat aorta strips precontracted with phenylephrine, in keeping with a NO-induced activation of the sGC as a mechanism that underlies the vasodilator effect. The products here described are new improved examples of NO-donor aspirins containing nitrooxy groups. They could represent an alternative to the use of aspirin in a variety of clinical applications.
No takes yet. Share an insight, caveat, or question.
Lazzarato et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: